Quantcast

Roche’s Tecentriq shows survival benefit over chemotherapy as an initial treatment in NSCLC

Roche’s study met a goal, comparing a lung cancer therapy Tecentriq with cisplatin and pemetrexed as the initial monotherapy compared in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).

Read more